Press Release | 07/27/2022
Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system
ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study.
Silo’s formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesia was reduced on day seven at the pre-dose time point. These results indicate that the dosing of Ketamine using a patent protected delivery system with Silo Pharma’s partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in a small animal study.
Eric Weisblum, CEO of Silo Pharma, commented, “These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction. This data is extremely promising for patients suffering from Fibromyalgia and Rheumatoid Arthritis. Additionally, I am delighted to report that Day seven and Day nine scores averaged zero (no erythema or swelling present) for all groups, which bodes extremely well for our planned toxicology study.”
About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit www.silopharma.com
Recent SILO News
- Silo Pharma Announces Positive Results for Intranasal PTSD Treatment • GlobeNewswire Inc. • 04/23/2024 12:15:00 PM
- Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic • GlobeNewswire Inc. • 04/10/2024 12:11:00 PM
- Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic • GlobeNewswire Inc. • 03/20/2024 12:30:00 PM
- Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain • GlobeNewswire Inc. • 03/18/2024 11:15:00 AM
- Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD • GlobeNewswire Inc. • 02/28/2024 01:25:00 PM
- Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery • GlobeNewswire Inc. • 02/14/2024 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 06:15:35 PM
- Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology • GlobeNewswire Inc. • 02/01/2024 03:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/31/2024 05:15:16 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:29:45 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:27:04 PM
- Silo Pharma Announces Positive Results in Alzheimer’s Disease Study • GlobeNewswire Inc. • 01/24/2024 01:55:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/23/2024 10:01:06 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/11/2024 05:15:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 09:30:11 PM
- Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD • GlobeNewswire Inc. • 01/04/2024 01:55:00 PM
- Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia • GlobeNewswire Inc. • 12/28/2023 01:25:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 09:13:38 PM
- Form 8-K12B - Notification that a class of securities of successor issuer is deemed to be registered pursuant to section 12(b) • Edgar (US Regulatory) • 12/20/2023 09:58:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:44:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/07/2023 11:13:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:05:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 09:55:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/01/2023 02:10:20 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM